NYSE American: TOVX · Theriva Biologics, Inc.Enhanced Equity Research · May 27, 2026
Equity Research Report
Analysis by Joseph Lefcoe
Enhanced Equity Research — Theriva Biologics, Inc. (TOVX)
Oncolytic Virus InnovatorClinical-Stage Micro-Cap BiotechPancreatic Cancer Pipeline

TOVX

Theriva Biologics, Inc. — Enhanced Equity Research
Current Price
$0.30
Market Cap
$13.7M
52-Week High
1.50
52-Week Low
0.16
HOLD
PT $1.33
+343% upside · Low conviction

Theriva Biologics — Clinical-Stage Oncolytic Virus Platform at an Inflection Point

Theriva Biologics (TOVX) is a clinical-stage biotech developing VCN-01, an oncolytic adenovirus designed to selectively replicate in tumor cells while degrading the tumor stroma. The company's lead program targets metastatic pancreatic ductal adenocarcinoma (PDAC), one of the most lethal cancers with a 5-year survival rate below 12%. The Phase 2b VIRAGE trial met its primary endpoints, demonstrating improved overall survival, progression-free survival, and duration of response versus standard-of-care chemotherapy alone — a meaningful clinical result in a disease with very few treatment options. In March 2026, the FDA provided alignment on Phase 3 trial design, marking a critical regulatory milestone.

However, significant execution risks remain. The company's cash runway extends only into Q1 2027 with $14.4M on hand, and launching a pivotal Phase 3 trial in PDAC will require substantially more capital — likely $50M+ over the trial duration. Theriva is pursuing warrant exercises ($8.7M potential) and ATM offerings, but dilution has been aggressive, with shares outstanding growing from ~1M post-reverse-split to 45.9M in 18 months. The stock trades at $0.30 — an 80% discount to the 52-week high of $1.50 — reflecting the market's skepticism about the company's ability to fund pivotal trials without a strategic partner.

The investment thesis hinges on binary outcomes: a pharma partnership or licensing deal for VCN-01 would be transformational, while failure to secure funding could leave the company unable to advance its most promising asset. The pipeline also includes VCN-01 in retinoblastoma (potential orphan indication) and VCN-12, a next-generation candidate from the VCN-X discovery platform. For risk-tolerant investors, the current valuation prices in minimal pipeline value, creating asymmetric upside if financing and clinical execution align — but the path is narrow and the dilution overhang is real.

Key Financial Metrics — Clinical-stage biotech — pre-revenue with significant cash constraints

Market Cap
$13.7M
45.9M shares outstanding
Revenue (TTM)
$0.3M
Grant & interest income only — pre-revenue biotech
EPS (TTM)
-$0.05
Q1 2026 reported · Improving from -$0.45 Q3 2025
Cash Position
$14.4M
As of March 31, 2026 · Net cash $10.4M
Burn Rate
~$1.6M/qtr
R&D down 88% in Q1 2026 post-VIRAGE completion
Pipeline Stage
Phase 3 Ready
VCN-01 — FDA EOP2 alignment for pivotal PDAC trial
Debt/Equity
0.11
$2.6M total debt · Low leverage
Cash Runway
Q1 2027
~9 months at current burn · Additional $8.7M warrant raise pending

Net Loss by Quarter ($ millions)

-$13.1M
Q2 2025
-$4.4M
Q3 2025
-$1.8M
Q4 2025
-$2.0M
Q1 2026

VCN-01 Oncolytic Adenovirus Platform

142
Patients Treated
VCN-01 administered across multiple cancer indications
88%
R&D Cost Reduction
Q1 2026 R&D fell to $355K post-VIRAGE completion
Phase 3
FDA Alignment
EOP2 meeting confirmed pivotal PDAC trial design
Jun 2026
Special Stockholder Meeting
Vote on authorization to issue 16.2M shares upon warrant exercise at $0.54, potentially raising ~$8.7M for operations.
H2 2026
Phase 2a Dosing Study Initiation
Planned Phase 2a study evaluating VCN-01 dosing frequency in metastatic PDAC patients to optimize pivotal trial design.
H2 2026
Retinoblastoma Regulatory Interactions
Continued regulatory discussions regarding proposed pivotal clinical trial of VCN-01 in retinoblastoma — potential orphan drug pathway.
2026-2027
VCN-01 Manufacturing Scale-Up
Ongoing scale-up activities to support commercial-grade manufacturing for anticipated Phase 3 supply needs.
2027+
Phase 3 PDAC Trial Initiation
Pivotal trial in metastatic PDAC contingent on securing adequate funding — likely requires partnership or significant capital raise.

Forward Estimates, Surprises & Insider Activity

Forward Earnings Estimates

FY+1 EPS Consensus-$0.20
FY+2 EPS Consensus-$0.20
PEG RatioN/A
Forward P/EN/A (unprofitable)
EPS Revisions (90d)↑0 ↓0 (Stable — minimal analyst coverage with no recent EPS revisions)
Guidance AccuracyNo formal guidance issued — clinical-stage company

Earnings Surprise Track Record

Q1 2026 Est: -$0.05 Act: -$0.05 0%
Q4 2025 Est: -$0.37 Act: -$0.12 67.6%
Q3 2025 Est: -$4.19 Act: -$0.45 89.3%
Q2 2025 Est: -$2.00 Act: -$1.93 3.5%
Beat Rate75% (3 beats, 1 in-line over last 4 quarters)

Insider Activity (90 Days)

Net Buying/Selling$0 — No insider purchases or sales in 90 days
Sell/Buy RatioN/A — No transactions recorded
Neutral to Negative
CEO Steven A. Shallcross and other officers have not made open-market purchases despite stock trading near 52-week lows. Only 0.67% insider ownership.

Relative Valuation vs. Competitors

CompanyMarket CapPipeline StageCash RunwayYTD Change
Theriva Biologics$15.5MPhase 2b complete · Phase 3 alignedQ1 2027 ($14.4M)+32%
CG Oncology$5.71BPhase 3 (bladder cancer)H1 2029 ($903M)+163%
Genelux~$110MPhase 3 (ovarian cancer)Q3 2026 (~$21M)-42%
Oncolytics Biotech~$110MPhase 2 (colorectal)Going concern riskVolatile
TOVX is the smallest by market cap among oncolytic virus peers but carries a differentiated adenovirus platform with FDA Phase 3 alignment. Cash runway is tight but better than ONCY and GNLX. CG Oncology is the clear sector leader at $5.7B market cap.

Price Targets & Scenarios

ScenarioPrice TargetAssumptionsProbability
Pivotal Trial Funded & Initiated$4.00Phase 3 PDAC trial launched with adequate funding via warrant exercise + partnership. VCN-01 replicates VIRAGE efficacy. Potential orphan drug designation for retinoblastoma. Share dilution manageable.20%
Slow Progression With Modest Catalysts$1.00Warrant exercise partially funds Phase 3 prep. Additional ATM dilution pressures price. Phase 2a dosing study initiated. No partnership announced in 2026. Cash extended into mid-2027.50%
Funding Gap Delays Pivotal Trial$0.10Warrant exercise fails or raises insufficient capital. Cash runs out Q1 2027 with no Phase 3 underway. Further dilutive financing at deep discount. Potential reverse split risk or delisting concerns.30%

Probability-Weighted Target: $1.33 (+343% from current price)

$1.33
Weighted
Bull $4.0020%
Base $1.0050%
Bear $0.1030%

Analyst Consensus

Maxim Group (J. McCarthy)
$1.00
Upgraded Hold to Buy · Mar 2026
Alliance Global Partners
$4.00
Hold · PT lowered from $7.00
Zacks Consensus
$6.50
Strong Buy · Range $6.00-$7.00
Coverage Pending
Limited sell-side coverage for micro-cap
Moderate Buy — 3 Buy, 1 Hold, 0 Sell. Consensus reflects optimism around VCN-01 Phase 3 readiness, offset by dilution risk and limited cash runway.

Key Levels & Options Intelligence

S/RSupport & Resistance

52-Week High
$1.50
Resistance (R2)
$0.37
Resistance (R1)
$0.32
Current Price
$0.31
Support (S1)
$0.16
Support (S2)
$0.11
52-Week Low
$0.163

OptOptions & Sentiment

  • Implied Volatility: Not available — micro-cap with extremely limited options market
  • Short Interest: 8.51M shares short (Apr 30) — up 234% from Apr 15
  • Short % of Float: ~25.4% — elevated bearish positioning
  • Put/Call Ratio: Not available — insufficient options liquidity
  • Average Volume: ~2.02M shares/day · Recent spikes to 79.7M on catalysts
  • Days to Cover: ~1.0 day on normalized volume
  • Beta: 0.52 — historically decoupled from broad indices
  • Institutional Ownership: 0.55% — 18 holders · Dominated by retail investors

Systematic Conviction Score: 45/100 (Low)

100
Analyst Alignment
30%
5
FCF Visibility
25%
25
Catalyst Clarity
20%
75
Valuation Safety
15%
20
Mgmt Quality
10%
Despite unanimous analyst Buy ratings, the conviction score is dragged down by zero free cash flow visibility, no near-term catalysts within 90 days, minimal insider ownership (0.67%), and a going concern flag from auditors. The massive valuation gap to analyst targets provides theoretical safety but depends entirely on binary outcomes.

Risk Assessment & Insider Signals

!Risk Factors

  • Clinical Trial Failure Risk: VCN-01's Phase 3 trial in metastatic PDAC has not yet begun. Phase 2b VIRAGE data were encouraging but in a small patient population. Phase 3 trials in pancreatic cancer have historically high failure rates (~85%).
  • Cash Runway & Dilution Risk: Cash of $14.4M extends only into Q1 2027. Shares outstanding surged from 35.7M to 45.9M in Q1 2026. An additional 16.2M warrant shares await approval, representing ~35% further dilution.
  • Going Concern & Financing Risk: Auditors flagged substantial doubt about the company's ability to continue as a going concern. Accumulated deficit stands at $335M. Entirely dependent on external financing to survive beyond Q1 2027.
  • Regulatory & Approval Risk: FDA provided positive EOP2 feedback but no approval guarantee. Phase 3 trial design may require IND amendments. Any clinical hold or safety signal could delay the program by years.
  • Competition Risk: The oncolytic virus market ($1.5B+ by 2030) is increasingly crowded. Genelux, Replimune, Candel Therapeutics, and Amgen compete for clinical and commercial space in overlapping indications.
  • Market Adoption Risk: Even with Phase 3 success, Theriva has no commercial infrastructure. A micro-cap with 20 employees would need a pharma partner. Oncolytic virus mechanism may face physician adoption resistance.

OOwnership & Insider Signals

  • Institutional Ownership — Very Low at 6.17%: Only 18 institutional holders with approximately 250,675 shares. Extremely low participation reflects micro-cap illiquidity, clinical-stage risk, and limited analyst coverage.
  • Anson Funds Management LP — Largest Holder at ~6.1%: Toronto-based multi-strategy hedge fund with 139,046 shares (~$192K). Known for micro-cap biotech and event-driven positions.
  • Geode Capital Management LLC — 212,087 Shares: Index-tracking strategies for Fidelity. Largest nominal share count among institutions at ~0.63% ownership. Passive/index-driven.
  • Other Institutional Holders: Two Sigma (61,837 shares), MSD Partners (27,316 shares), plus small allocations from BlackRock, Vanguard, Fidelity, UBS, and Virtu Financial. All positions are tiny by dollar value.
  • Insider Ownership — Minimal at 0.67%: Officers and directors collectively own only 0.67% of shares outstanding. Low alignment between management and shareholders.
  • Heavy Warrant Overhang: 45.9M shares outstanding as of Q1 2026 (up from 35.7M at year-end 2025). Additional 16.2M warrant shares at $0.54 pending stockholder approval. Fully diluted count could exceed 62M.

Quantified Risk Assessment

Severity Risk Factor Prob. PT Impact
High Clinical Trial Failure Risk 45% -70%
High Cash Runway & Dilution Risk 90% -35%
High Going Concern & Financing Risk 70% -50%
Medium Regulatory & Approval Risk 30% -40%
Medium Competition Risk 50% -25%
Medium Market Adoption Risk 40% -30%

Summary

Rating
HOLD
Conviction
Low
Price Target
$1.33
Timeframe
12-18 mo
Upside
+343%
Position Size
1%-2%

Entry Strategy

1
Tranche 1 — 40%
~$0.28-0.32
Starter position at current levels. Establishes exposure ahead of June warrant vote catalyst.
2
Tranche 2 — 35%
~$0.18-0.22
Add on pullback toward S1 support ($0.16-0.20) if warrant vote fails or market sells off. Average down only if thesis intact.
3
Tranche 3 — 25%
~$0.40-0.55
Add on confirmation — only if Phase 2a dosing study initiates or partnership materializes. Pay up for reduced risk.
IMPORTANT DISCLAIMER: This analysis is for educational and research purposes only. Not financial advice. Past performance does not guarantee future results. Consult qualified financial professionals before making investment decisions. All investments carry risk of loss. The information presented is based on publicly available data as of May 27, 2026.